1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Schibli, D.J.
Montelaro, R.C.
Vogel, H.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
H2 N
16.023
AMINO GROUP
non-polymer
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
40
9570
9578
10.1021/bi010640u
11583156
The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles.
2001
10.2210/pdb1jau/pdb
pdb_00001jau
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
2569.979
TRANSMEMBRANE GLYCOPROTEIN (GP41)
residues 665-683
1
syn
polymer
no
yes
KWASLWNWFNITNWLWYIK(NH2)
KWASLWNWFNITNWLWYIKX
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_nmr_software
pdbx_nmr_spectrometer
pdbx_struct_assembly
pdbx_struct_oper_list
struct_conn
struct_site
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2001-10-17
1
1
2008-04-27
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
_pdbx_nmr_spectrometer.model
_struct_conn.pdbx_leaving_atom_flag
_struct_site.pdbx_auth_asym_id
_struct_site.pdbx_auth_comp_id
_struct_site.pdbx_auth_seq_id
Minimized Average Structure for this deposition
RCSB
Y
RCSB
2001-05-31
REL
REL
This peptide was chemically synthesized. The sequence of the peptide is naturally found in Human Immunodeficiency Virus (HIV).
sample
This structure was determined using standard 2D homonuclear techniques.
structures with the lowest energy
200
40
2D NOESY
2D TOCSY
DQF-COSY
2D NOESY
2D TOCSY
200 mM DPC-d38
3.51
ambient
310
K
Structures were initially generated using CNS. Ambiguous and unassigned noe constraints
were then used in conjuction with matrix relaxation analysis using the program ARIA.
distance geometry,
simulated annealing,
molecular dynamics,
matrix relaxation
1.6 mM synthetic gp41 peptide, 200 mM perdeuterated dodecylphosphocholine
90% H2O/10% D2O
1.6 mM synthetic gp41 peptide, 200 mM perdeuterated dodecylphosphocholine
100% D2O
Bruker
collection
XwinNMR
2.6
F.Delaglio, S.Grzesiek, G.Vuister, G.Zhu, J.Pfeifer, A.Bax
processing
NMRPipe
1.8
B.Johnson, R.A.Blevins
data analysis
NMRView
4.1.3
A.T.Brunger, P.D.Adams, G.M.Clore, W.L.Delano, P.Gros, R.W.Grosse-Kunstleve,
J.-S.Jiang, J.Kuszewski, M.Nilges, N.S.Pannu, R.J.Read, L.M.Rice, T.Simonson, G.L.Warren
structure solution
CNS
1.0
M.Nilges, J.Linge, S.O'Donoghue
iterative matrix relaxation
ARIA
1.0
A.T.Brunger, P.D.Adams, G.M.Clore, W.L.Delano, P.Gros, R.W.Grosse-Kunstleve,
J.-S.Jiang, J.Kuszewski, M.Nilges, N.S.Pannu, R.J.Read, L.M.Rice, T.Simonson, G.L.Warren
refinement
CNS
1.0
500
Bruker
AVANCE
800
Varian
INOVA
LYS
1
n
1
LYS
1
A
TRP
2
n
2
TRP
2
A
ALA
3
n
3
ALA
3
A
SER
4
n
4
SER
4
A
LEU
5
n
5
LEU
5
A
TRP
6
n
6
TRP
6
A
ASN
7
n
7
ASN
7
A
TRP
8
n
8
TRP
8
A
PHE
9
n
9
PHE
9
A
ASN
10
n
10
ASN
10
A
ILE
11
n
11
ILE
11
A
THR
12
n
12
THR
12
A
ASN
13
n
13
ASN
13
A
TRP
14
n
14
TRP
14
A
LEU
15
n
15
LEU
15
A
TRP
16
n
16
TRP
16
A
TYR
17
n
17
TYR
17
A
ILE
18
n
18
ILE
18
A
LYS
19
n
19
LYS
19
A
LYS
19
n
20
NH2
20
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
-27.22
1.60
122.70
95.48
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
3
-10.06
1.60
122.70
112.64
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
4
-38.44
1.60
122.70
84.26
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
5
-42.36
1.60
122.70
80.34
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
6
-22.93
1.60
122.70
99.77
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
7
-11.84
1.60
122.70
110.86
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
9
-56.58
1.60
122.70
66.12
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
10
-38.24
1.60
122.70
84.46
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
11
-20.23
1.60
122.70
102.47
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
12
-13.54
1.60
122.70
109.16
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
13
-20.27
1.60
122.70
102.43
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
15
-46.75
1.60
122.70
75.95
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
16
-47.04
1.60
122.70
75.66
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
19
-33.08
1.60
122.70
89.62
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
20
-11.75
1.60
122.70
110.95
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
21
-52.26
1.60
122.70
70.44
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
23
-9.73
1.60
122.70
112.97
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
25
-28.81
1.60
122.70
93.89
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
27
-11.42
1.60
122.70
111.28
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
30
-9.71
1.60
122.70
112.99
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
33
-29.41
1.60
122.70
93.29
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
34
-61.35
1.60
122.70
61.35
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
35
-47.13
1.60
122.70
75.57
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
39
-27.67
1.60
122.70
95.03
A
A
A
O
C
N
LYS
LYS
NH2
19
19
20
Y
1
A
ALA
3
-78.02
30.38
1
A
LEU
5
-140.42
-26.28
2
A
ALA
3
-79.74
29.42
2
A
THR
12
-68.33
1.66
3
A
THR
12
-68.75
0.56
4
A
ALA
3
-79.15
27.58
5
A
THR
12
-66.30
1.19
7
A
ALA
3
-75.59
25.28
7
A
THR
12
-68.58
2.11
7
A
ILE
18
-76.51
-70.60
8
A
ALA
3
-77.79
24.97
9
A
ALA
3
-78.20
23.27
10
A
ALA
3
-73.79
22.13
11
A
ALA
3
-75.84
27.94
11
A
THR
12
-67.49
1.83
12
A
ALA
3
-69.83
5.62
13
A
THR
12
-68.17
0.70
14
A
ALA
3
-76.55
21.21
15
A
ALA
3
-75.37
27.72
15
A
THR
12
-67.67
0.61
17
A
THR
12
-67.35
1.82
19
A
TRP
2
-153.52
26.55
20
A
ALA
3
-77.27
21.18
21
A
ALA
3
-77.48
23.03
22
A
ALA
3
-77.43
24.78
23
A
ALA
3
-78.68
22.47
24
A
ALA
3
-78.40
29.14
24
A
SER
4
-141.32
53.62
24
A
LEU
5
-144.91
-16.47
26
A
SER
4
-98.30
34.39
26
A
THR
12
-67.18
0.63
27
A
ALA
3
-77.59
23.97
28
A
THR
12
-68.64
3.72
29
A
ALA
3
-78.59
25.32
30
A
ALA
3
-75.39
27.72
30
A
THR
12
-69.43
5.08
31
A
ALA
3
-78.83
30.76
31
A
LEU
5
-140.93
-3.25
31
A
THR
12
-67.11
2.16
32
A
ALA
3
-78.56
24.80
33
A
ALA
3
-78.89
31.10
34
A
ALA
3
-69.65
11.92
34
A
ILE
18
-82.87
-74.70
35
A
ALA
3
-77.94
30.26
37
A
SER
4
-99.56
30.71
38
A
ALA
3
-79.17
30.52
38
A
THR
12
-68.20
0.11
38
A
ILE
18
-96.07
-74.92
40
A
TRP
2
-69.64
5.01
40
A
ALA
3
-68.05
5.41
NMR Solution Structure of the Trp-Rich Peptide of HIV gp41 Bound to DPC Micelles
1
N
N
A
LEU
5
A
LEU
5
HELX_P
A
ASN
10
A
ASN
10
1
1
6
A
ASN
10
A
ASN
10
HELX_P
A
LYS
19
A
LYS
19
1
2
10
covale
1.328
both
A
LYS
19
A
C
LYS
19
1_555
A
NH2
20
A
N
NH2
20
1_555
covale
1.908
one
A
LYS
19
A
O
LYS
19
1_555
A
NH2
20
A
N
NH2
20
1_555
VIRAL PROTEIN
amphipathic alpha helix, Viral protein
ENV_HV1H3
UNP
1
665
P04624
KWASLWNWFNITNWLWYIK
665
683
1JAU
1
19
P04624
A
1
1
19
BINDING SITE FOR RESIDUE NH2 A 20
A
NH2
20
Software
2
A
TRP
16
A
TRP
16
2
1_555
A
LYS
19
A
LYS
19
2
1_555